Mylan ( Mylan )

Mylan

Mylan's picture

Mylan is one of the world’s leading generics and specialty pharmaceutical companies, providing products to customers in approximately 150 countries and territories. The company maintains one of the industry’s broadest and highest quality product portfolios, which is regularly bolstered by an innovative and robust product pipeline. With a workforce of more than 18,000, Mylan has attained leading positions in key international markets through its wide array of dosage forms and delivery systems, significant manufacturing capacity, global commercial scale and a committed focus on quality and customer service.

Mylan press release, blog etc

06/11/2018 - 17:20 Americares Honors Mylan with Power of Partnership Award
06/04/2018 - 01:49 U.S. FDA Approves Mylan and Biocon's Fulphila (pegfilgrastim-jmdb), the First Biosimilar to Neulasta
05/16/2018 - 12:08 Mylan Announcement of Redemption of Certain Notes Due 2019
05/14/2018 - 12:55 Mylan and West Virginia University Join Forces to Inspire West Virginia Youth Through STEM-CARE
05/09/2018 - 07:08 Mylan Statement on Supply of EpiPen (epinephrine injection, USP) Auto-Injectors from Meridian Medical Technologies, a Pfizer company
04/25/2018 - 08:30 Mylan Adds to Growing Women's Healthcare Portfolio with Launch of Generic for Oral Contraceptive Yaz
04/21/2018 - 11:08 Mylan Presents Equivalence Data on Glatiramer Acetate Compared to Copaxone at American Academy of Neurology 70th Annual Meeting
04/11/2018 - 11:19 Mylan to Leverage its World-Class Scientific Platform to Develop a Novel Delivery for Meloxicam, a Non-Opioid Pain Medication
04/11/2018 - 09:28 Investor Day Highlights Durability of Mylan's Global Platform
04/11/2018 - 07:00 Mylan Partners with Fujifilm Kyowa Kirin Biologics to Commercialize Biosimilar to Humira (adalimumab)
04/10/2018 - 05:39 Mylan to Acquire the Global Marketing Rights to a Once-monthly Glatiramer Acetate Product through an Investment and Partnership with Israeli Company Mapi Pharma
04/06/2018 - 03:19 Mylan Strengthens Its Capital Structure by Extending Its Debt Maturities with a Successful $1.5 Billion Bond Offering
03/29/2018 - 14:27 Mylan Announcement of Redemption of Notes
03/28/2018 - 06:14 Mylan Introduces Symfi Triple Combo Once-Daily HIV Treatment in the U.S.
03/27/2018 - 00:29 Mylan and Biocon Receive Approvals from the European Commission and TGA Australia for Semglee, Biosimilar Insulin Glargine
03/21/2018 - 05:55 Mylan to Host Investor Day on April 11, 2018, in New York City
03/20/2018 - 05:06 Mylan Adds to Growing Oncology Portfolio with Launch of Generic Mutamycin Injection
03/02/2018 - 10:04 Mylan to Introduce Two New Cost-Saving HIV Combination Treatments in the U.S.